Case Study

12.5× Titer Boost Accelerates CAR-T Program to IND Filing

Cell Therapy
LVV
Testing
Viral Vectors



Optimizing CAR LVV
A biotechnology innovator focused on cell therapies faced a significant hurdle in the development of their flagship CAR-T program. By partnering with Minaris Advanced Therapies, the client utilized plasmid engineering and parallel process development services to achieve a 12.5-fold increase in infectious titer.

Download PDF
PDF preview